FY26 revenue growth of 15-16%
Management expects full-year revenue growth in mid-teens (15-16%), driven by strong Q4.
ANTHEM / guidance tracker
Keep management guidance in view.
Anthem Biosciences · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY26 EBITDA and PAT growth above 20%
EBITDA and PAT growth guidance of 20%+ for FY26, with margin profile remaining steady.
Unit 4 capex of ~1,000 crore over two years
Phase 1 expansion at Unit 4 involves ~1,000 crore capex, with major spending in FY27.